A Phase Ia/IIa trial of AVID100, an anti-EGFR antibody-drug conjugate

Authors
Category Primary study
JournalCancer Research
Year 2019
This article has no abstract
Epistemonikos ID: 402bf189e6fe635ace1b9c6c4bb510cc76078942
First added on: Feb 11, 2025